CRBU (Caribou Biosciences) Institutional Ownership: 36.88% (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRBU Caribou Biosciences Inc CRBU
64 GF Score
Price $1.58
GF Value $1.42
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Institutional Ownership?

Caribou Biosciences CRBU 64 Institutional Ownership is 36.88% as of Aug. 17, 2026. GuruFocus rates CRBU with a GF Score™ of 64/100 and a GF Value™ of $1.42 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Caribou Biosciences's institutional ownership is 36.88%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Caribou Biosciences's Insider Ownership is 1.93%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Caribou Biosciences's Float Percentage Of Total Shares Outstanding is 96.33%.

Caribou Biosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Institutional Ownership Chart

Caribou Biosciences Historical Data

The historical data trend for Caribou Biosciences can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 9.51 9.64 10.30 9.94 9.87 10.22 10.10 10.30 19.72 20.21
CRBU
64GF Score
Caribou Biosciences Inc CRBU
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 36.88% mean?
Caribou Biosciences (CRBU) has a Institutional Ownership of 36.88% as of Aug. 17, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Caribou Biosciences and its competitors.
Is Caribou Biosciences' Institutional Ownership too high?
Caribou Biosciences' current Institutional Ownership is 36.88%. Overall, Caribou Biosciences has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Institutional Ownership compare to SMNR and ARCT?
Caribou Biosciences' Institutional Ownership of 36.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current Institutional Ownership is 36.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.42, compared to a current price of $1.58 — trading 11.3% above its estimated fair value. The current Institutional Ownership is 36.88%. Caribou Biosciences' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Institutional Ownership is 36.88% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued. The current stock price of $1.58 is trading 11.3% above its estimated GF Value™ of $1.42. GuruFocus considers Caribou Biosciences to be Modestly Overvalued.

Key valuation signals for CRBU:

  • Institutional Ownership: 36.88%
  • GF Value™: $1.42 vs. price of $1.58 (11.3% above fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
64GF Score

Get the complete analysis for CRBU

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.58
Price
$1.42
GF Value